Learning Objective 1: To present findings from a local, retrospective, open label, database study on intravenous ketamine for ultraresistant depression
|
|
|
|
|
|
Learning Objective 2: To investigate the response rate of intravenous ketamine and clinical predictors of effectiveness in this study and in the literature
|
|
|
|
|
|
Learning Objective 3: To discuss future directions in clinical and in research settings for ketamine as an antidepressant
|
|
|
|
|
|